EGFR inhibitors
The firm's next move will be to pit aumolertinib against AstraZeneca's Tagrisso, the new standard of care in EGFR-mutated NSCLC.
Taiho Pharmaceutical Acquires Cullinan Pearl, Regaining Rights to EGFR Inhibitor
Taiho licensed the drug to Cullinan in 2019 but has now acquired Cullinan subsidiary Cullinan Pearl to resume codevelopment and commercialization of the program.
The company is conducting a clinical trial of a pan-variant inhibitor for KIT-mutant GIST and hopes to advance an EGFR pan-variant inhibitor to the clinic soon.
Black Diamond Therapeutics to Discontinue ErbB Inhibitor Program, Lay Off 30 Percent of Workforce
The company is shifting its focus to developing EGFR and BRAF inhibitors and believes cutting staff will extend its cash runway into Q3 2024.
Black Diamond Therapeutics Doses First Patient in Recurrent EGFR-Mutant Glioblastoma, NSCLC Trial
The trial is designed to assess BDTX-1535 for patients with brain or lung cancers harboring EGFR alterations that haven't responded to standard treatment.